Teva Pharmaceutical Industries Limited (NYSE:TEVA) shows upbeat performance surges 1.01% to close at $50.90 as Teva Pharmaceutical Industries Ltd. (TEVA) reported that had a third patent on its top-selling multiple sclerosis drug, Copaxone, inauthenticated Thursday by a USA agency, a additional blow to its offer to block generic versions of a drug that accounts for 20 percent of its income. The most optimist securities analyst among the 15 who monitor the stock believes that the stock can reach $100, however, the pessimist price target for the company is $57. The difference between the expected and actual EPS was $0.05/share, which represents an Earnings surprise of 4.2%. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services.
Advertisement
07/25/2016 – Teva Pharmaceutical Industries Limited had its “overweight” rating reiterated by analysts at JP Morgan.
Teva Pharmaceutical Industries Limited is a global pharmaceutical company. According to these analysts, the Low Revenue Estimate for Teva Pharmaceutical Industries Limited is 5.65 Billion and the High Revenue Estimate is 6.29 Billion. The company had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.86 billion. Now the stock has been rated as “Buy” from 2 Analysts. Beacon plans to engage global pharmaceutical partners to facilitate discovery and early stage development. Nonetheless, 10 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. They now have a Dollars 61 price target on the stock. The stock has received “HOLD” rating after consensus analysis from analysts. The stock is now trading down its SMA 50 of $53.43. The company has a market cap of $51.22 billion.
GG, was trading -25.22% below its 52-week high and 61.70% above its 52-week low. The stock price of SNY is moving down from its 20 days moving average with -2.91% and isolated negatively from 50 days moving average with -5.65%. The Company Touched its 52-Week High on Dec 30, 2015 and 52-Week Low on Jun 27, 2016. Shares knocked down -0.16% to trade at $38.41 in most recent trading session. Teva Pharmaceutical Industries Limited P/E (price to earnings) ratio is 33.64 and Forward P/E ratio of 8.48. It maintained return on assets (ROA) for the last twelve months at 48.31%. The stock held beta value of -0.80, while return on equity ratio was -226.10%. The company net profit margin is 2.80% A look on the firm performance, its monthly performance is -0.38% and a quarterly performance of -5.70%.
Advertisement
Oppenheimer has upgraded Teva Pharmaceutical (NYSE:TEVA) from Perform to Outperform in a statement released on 9/02/2016. Year to Date performance value (YTD perf) value is -21.75%.
